文献速递前列腺癌

转移性去势抵抗性前列腺癌中循环肿瘤DNA分数的预后价值:ProBio平台试验结果

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.
PubMed 文献 · Eur Urol Oncol · 2025-04-21

本研究基于ProBio试验分析220例转移性去势抵抗性前列腺癌患者,评估基线循环肿瘤DNA(ctDNA)不可测及ctDNA水平与生存的剂量反应关系。结果显示,与ctDNA不可测组相比,医生选择组至无临床获益时间(NLCB)缩短60%(STR 0.40,90% CrI 0.31-0.51),总生存(OS)缩短51%(STR 0.49,90% CrI 0.38-0.61)。ctDNA分数每增加10个百分点,NLCB和OS时间均减少10%。

要点

  • 基线ctDNA不可测的mCRPC患者预后显著优于可测者。
  • ctDNA分数与生存呈剂量反应关系,每增10点生存时间减10%。
  • ctDNA不可测亚组或可考虑治疗降阶梯和减少监测强度。

核心结论

  • 基线ctDNA不可测预示mCRPC患者更优预后,提示该亚组可考虑治疗降阶梯和更宽松的监测。

研究设计与样本

  • 共纳入220例患者,其中139例ctDNA可测(医生选择组56例,研究组83例),81例ctDNA不可测。
  • 采用贝叶斯生存模型评估生存结局,结果以生存时间比(STR)表示;剂量反应关系采用零膨胀模型估计。

主要发现

  • 与ctDNA不可测组相比,医生选择组至无临床获益时间(NLCB)缩短60%(STR 0.40,90% CrI 0.31-0.51)。
  • 与ctDNA不可测组相比,医生选择组总生存(OS)缩短51%(STR 0.49,90% CrI 0.38-0.61)。
  • 研究组与ctDNA不可测组比较观察到类似结果。
  • 与ctDNA分数2.5%亚组相比,ctDNA不可测组NLCB时间延长2倍(STR 2.05,90% CrI 1.66-2.57),OS延长1.6倍(STR 1.63,90% CrI 1.33-2.05)。
  • ctDNA分数每增加10个百分点,NLCB和OS时间均减少10%。

临床怎么用

  • 基线ctDNA不可测可作为mCRPC预后良好的生物标志物,辅助识别适合治疗降阶梯和减少监测强度的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The aim of this study was to evaluate the prognostic value of undetectable circulating tumor DNA (ctDNA) and the dose-response relationship between ctDNA levels and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC). METHODS: We analyzed data for patients enrolled in the ProBio trial up to November 2022 who received an androgen receptor pathway inhibitor or taxane. We compared survival outcomes between patients with undetectable ctDNA and those with detectable ctDNA randomized to physician's choice or investigational arms. Time to no longer clinically benefiting (NLCB) and overall survival (OS) were assessed using Bayesian survival models, with results reported as survival time ratios (STRs). Dose-response relationships were estimated using spike-at-zero models. KEY FINDINGS AND LIMITATIONS: A total of 220 patients were included, of whom 139 had detectable ctDNA (56 in the physician's choice arm, 83 in investigational arms) and 81 had undetectable ctDNA. In comparison to the undetectable ctDNA group, the physician's choice arm had 60% shorter time to NLCB (STR 0.40, 90% credible interval [CrI] 0.31-0.51) and 51% shorter OS (STR 0.49, 90% CrI 0.38-0.61). Similar results were observed in comparison to the investigational arms. Dose-response analysis revealed that the undetectable ctDNA group had twofold longer time to NLCB (STR 2.05, 90% CrI 1.66-2.57) and 1.6-fold longer OS (STR 1.63, 90% CrI 1.33-2.05) in comparison to the subgroup with a ctDNA fraction of 2.5%. Every 10-point increment in the ctDNA fraction corresponded to a 10% reduction in NLCB and OS times. CONCLUSIONS AND CLINICAL IMPLICATIONS: Undetectable ctDNA at baseline predicts superior prognosis in mCRPC, suggesting potential for treatment de-escalation and less intensive monitoring for this subgroup of patients. This trial is registered on ClinicalTrials.gov as NCT03903835.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Crippa A, Laere B, Discacciati A, et al. Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial. Eur Urol Oncol. 2025. PMID: 40263079. doi:10.1016/j.euo.2025.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。